ReWalk Robotics (LFWD) 10-Q 9 Aug 19 2019 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Aug. 09, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	ReWalk Robotics Ltd.
Entity Central Index Key	0001607962
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Common Stock, Shares Outstanding		7,289,110
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity File Number	001-36612
Entity Interactive Data Current	Yes
Entity Incorporation State Country Code	L3

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands		Jun. 30, 2019	Dec. 31, 2018
CURRENT ASSETS
Cash and cash equivalents		$ 24,054	$ 9,546
Trade receivable, net		417	758
Prepaid expenses and other current assets		1,384	693
Inventories		2,661	2,240
Total current assets		28,516	13,237
LONG-TERM ASSETS
Restricted cash and other long term assets		1,110	1,099
Operating lease right-of-use assets		1,893
Property and equipment, net		453	626
Total long-term assets		3,456	1,725
Total assets		31,972	14,962
CURRENT LIABILITIES
Current maturities of long term loan		3,493	1,722
Current maturities of operating leases		635
Trade payables		2,817	2,328
Employees and payroll accruals		638	650
Deferred revenues		381	237
Other current liabilities		406	445
Total current liabilities		8,370	5,382
LONG-TERM LIABILITIES
Long term loan, net of current maturities		4,373	6,965
Deferred revenues		489	431
Non-current operating leases		1,404
Other long-term liabilities		68	239
Total long-term liabilities		6,334	7,635
Total liabilities		14,704	13,017
COMMITMENTS AND CONTINGENT LIABILITIES
Shareholders' equity:
Share capital Ordinary share of NIS 0.25 par value-Authorized: 60,000,000 shares at June 30, 2019 and 10,000,000 shares at December 31, 2018; Issued and outstanding: 7,289,110 and 2,813,087 shares at June 30, 2019 and December 31, 2018, respectively	[1]	503	193
Additional paid-in capital		178,270	154,670
Accumulated deficit		(161,505)	(152,918)
Total shareholders' equity		17,268	1,945
Total liabilities and shareholders' equity		$ 31,972	$ 14,962
[1]	Reflects one-for-twenty-five reverse share split that became effective on April 1, 2019. See Note 7a to the condensed consolidated financial statements

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Ordinary shares, par value (in NIS per share)	$ 0.25	$ 0.25
Ordinary shares, authorized	60,000,000	10,000,000
Ordinary shares, issued	7,289,110	2,813,087
Ordinary shares, outstanding	7,289,110	2,813,087

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Income Statement [Abstract]
Revenues	$ 877	$ 1,770	$ 2,458	$ 3,349
Cost of revenues	442	1,003	1,097	1,900
Gross profit	435	767	1,361	1,449
Operating expenses:
Research and development, net	1,860	1,897	3,274	4,048
Sales and marketing	1,531	1,925	3,118	4,261
General and administrative	1,279	2,221	2,779	4,258
Total operating expenses	4,670	6,043	9,171	12,567
Operating loss	(4,235)	(5,276)	(7,810)	(11,118)
Financial expenses, net	353	522	771	1,007
Loss before income taxes	(4,588)	(5,798)	(8,581)	(12,125)
Income taxes (tax benefit)	(1)	(1)	6	(1)
Net loss	$ (4,587)	$ (5,797)	$ (8,587)	$ (12,124)
Net loss per ordinary share, basic and diluted	$ (0.88)	$ (4.42)	$ (2.03)	$ (9.65)
Weighted average number of shares used in computing net loss per ordinary share, basic and diluted	5,213,446	1,310,870	4,236,788	1,256,514

Condensed Statements of Changes

Condensed Statements of Changes in Shareholders' Equity (Deficiency) (Unaudited) - USD ($) $ in Thousands		Ordinary Share		Receivables on account of shares	Additional paid-in capital	Accumulated deficit	Total
Balance at Dec. 31, 2017		$ 84			$ 134,843	$ (131,220)	$ 3,707
Balance, shares at Dec. 31, 2017		1,200,146
Cumulative effect to accumulated deficit from adoption of a new accounting standard						(23)	(23)
Share-based compensation to employees and non-employees					1,819		1,819
Issuance of ordinary shares upon exercise of options to purchase ordinary shares and RSUs by employees and non-employees			[1]
Issuance of ordinary shares upon exercise of options to purchase ordinary shares and RSUs by employees and non-employees, shares		8,154
Issuance of ordinary shares in a private placement agreement, net of issuance expenses in an amount of $830		$ 12			4,283		4,295
Issuance of ordinary shares in a private placement agreement, net of issuance expenses in an amount of $830, shares		164,715
Issuance of ordinary shares in at-the-market offering, net of issuance expenses in the amount		$ 4			1,058		1,062
Issuance of ordinary shares in at-the-market offering, net of issuance expenses in the amount, shares		46,340
Net loss						(12,124)	(12,124)
Balance at Jun. 30, 2018		$ 100			142,003	(143,367)	(1,264)
Balance, shares at Jun. 30, 2018		1,419,355
Balance at Mar. 31, 2018		$ 86		(42)	136,027	(137,570)	(1,499)
Balance, shares at Mar. 31, 2018		1,220,417
Share-based compensation to employees and non-employees					1,023		1,023
Issuance of ordinary shares upon exercise of options to purchase ordinary shares and RSUs by employees and non-employees			[1]
Issuance of ordinary shares upon exercise of options to purchase ordinary shares and RSUs by employees and non-employees, shares		3,459
Issuance of ordinary shares in a private placement agreement, net of issuance expenses in an amount of $830		$ 12			4,283		4,295
Issuance of ordinary shares in a private placement agreement, net of issuance expenses in an amount of $830, shares		164,715
Issuance of ordinary shares in at-the-market offering, net of issuance expenses in the amount		$ 2		42	670		714
Issuance of ordinary shares in at-the-market offering, net of issuance expenses in the amount, shares		30,764
Net loss						(5,797)	(5,797)
Balance at Jun. 30, 2018		$ 100			142,003	(143,367)	(1,264)
Balance, shares at Jun. 30, 2018		1,419,355
Balance at Dec. 31, 2018		$ 193			154,670	(152,918)	1,945
Balance, shares at Dec. 31, 2018		2,813,087
Share-based compensation to employees and non-employees					633		633
Issuance of ordinary shares upon exercise of options to purchase ordinary shares and RSUs by employees and non-employees		$ 1					1
Issuance of ordinary shares upon exercise of options to purchase ordinary shares and RSUs by employees and non-employees, shares		17,023
Issuance of ordinary shares in a "best efforts" offering, net of issuance expenses in the amount of $686	[2]	$ 52			3,632		3,684
Issuance of ordinary shares in a "best efforts" offering, net of issuance expenses in the amount of $686, shares	[2]	760,000
Exercise of pre-funded warrants and warrants	[2],[3]	$ 40			1,461		1,501
Exercise of pre-funded warrants and warrants, shares	[2],[3]	584,087
Issuance of ordinary shares in a "Registered Direct" offerings , net of issuance expenses in the amount of $1,125	[2]	$ 115			8,010		8,125
Issuance of ordinary shares in a "Registered Direct" offerings , net of issuance expenses in the amount of $1,125, shares	[2]	1,650,248
Issuance of ordinary shares in a "Warrant exercise" agreement, net of issuance expenses in the amount of $1,019	[2]	$ 102			9,864		9,966
Issuance of ordinary shares in a "Warrant exercise" agreement, net of issuance expenses in the amount of $1,019,shares	[2]	1,464,665
Net loss						(8,587)	(8,587)
Balance at Jun. 30, 2019		$ 503			178,270	(161,505)	17,268
Balance, shares at Jun. 30, 2019		7,289,110
Balance at Mar. 31, 2019		$ 253			158,720	(156,918)	2,055
Balance, shares at Mar. 31, 2019		3,695,174
Share-based compensation to employees and non-employees					314		314
Issuance of ordinary shares upon exercise of options to purchase ordinary shares and RSUs by employees and non-employees		$ 1					1
Issuance of ordinary shares upon exercise of options to purchase ordinary shares and RSUs by employees and non-employees, shares		14,817
Exercise of pre-funded warrants and warrants	[2],[3]	$ 32			1,362		1,394
Exercise of pre-funded warrants and warrants, shares	[2],[3]	464,206
Issuance of ordinary shares in a "Registered Direct" offerings , net of issuance expenses in the amount of $1,125	[2]	$ 115			8,010		8,125
Issuance of ordinary shares in a "Registered Direct" offerings , net of issuance expenses in the amount of $1,125, shares	[2]	1,650,248
Issuance of ordinary shares in a "Warrant exercise" agreement, net of issuance expenses in the amount of $1,019	[2]	$ 102			9,864		9,966
Issuance of ordinary shares in a "Warrant exercise" agreement, net of issuance expenses in the amount of $1,019,shares	[2]	1,464,665
Net loss						(4,587)	(4,587)
Balance at Jun. 30, 2019		$ 503			$ 178,270	$ (161,505)	$ 17,268
Balance, shares at Jun. 30, 2019		7,289,110
[1]	Represents an amount lower than $1.
[2]	See Note 7f to the condensed consolidated financial statements.
[3]	See Note 7d to the condensed consolidated financial statements.

Condensed Statements of Chang_2

Condensed Statements of Changes in Shareholders' Equity (Deficiency) (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Registered Direct [Member]
Issuance expenses, amount	$ 1,125		$ 1,125
Best Efforts [Member]
Issuance expenses, amount			686
At-the-Market Offering [Member]
Issuance expenses, amount		$ 148		$ 198
Investment Agreement [Member]
Issuance expenses, amount		$ 830		$ 830
Warrant Exercise [Member]
Issuance expenses, amount	$ 1,019		$ 1,019

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands		6 Months Ended
		Jun. 30, 2019	Jun. 30, 2018
Cash flows used in operating activities:
Net loss		$ (8,587)	$ (12,124)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		173	229
Share-based compensation to employees and non-employees		633	1,819
Deferred taxes		(51)	(13)
Changes in assets and liabilities:
Trade receivables, net		341	(777)
Prepaid expenses, operating lease right-of-use assets and other assets		(632)	261
Inventories		(421)	627
Trade payables		399	652
Employees and payroll accruals		(12)	22
Deferred revenues and advances from customers		202	290
Other liabilities		(1)	(54)
Net cash used in operating activities		(7,956)	(9,068)
Cash flows used in investing activities:
Purchase of property and equipment			(3)
Net cash used in investing activities			(3)
Cash flows from financing activities:
Repayment of long term loan		(821)	(2,271)
Issuance of ordinary shares in at-the-market offering, net of issuance expenses paid in the amount of $109	[1]		1,150
Issuance of ordinary shares in investment agreement, net of issuance expenses in an amount of $300	[1]		4,700
Issuance of ordinary shares in "best efforts" offering, net of issuance expenses in the amount of $686	[1]	3,684
Issuance of ordinary shares in a "registered direct" offerings, net of issuance expenses in the amount of $1,035	[1]	8,215
Issuance of ordinary shares in a "warrant exercise" agreement, net of issuance expenses in the amount of $ 1,019	[1]	9,966
Exercise of pre-funded warrants and warrants	[1],[2]	1,429
Net cash provided by financing activities		22,473	3,579
Increase (decrease) in cash, cash equivalents, and restricted cash		14,517	(5,492)
Cash, cash equivalents, and restricted cash at beginning of period		10,347	15,423
Cash, cash equivalents, and restricted cash at end of period		24,864	9,931
Supplemental disclosures of non-cash flow information
At-the-market offering expenses not yet paid	[1]		89
Investment agreement issuance cost not yet paid	[1]		405
"Registered direct" offerings issuance cost not yet paid	[1]	90
Classification of inventory to property and equipment, net			148
Cashless exercise of pre-funded warrants	[1],[2]	72
Initial recognition of operating lease right-of-use assets		2,099
Initial recognition of operating lease liabilities		(2,249)
Supplemental cash flow information:
Cash and cash equivalents		24,054	9,094
Restricted cash included in other long term assets		810	837
Total Cash, cash equivalents, and restricted cash		$ 24,864	$ 9,931
[1]	See Note 7f to the condensed consolidated financial statements.
[2]	See Note 7d to the condensed consolidated financial statements.

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
At-the-Market Offering [Member]
Issuance expenses paid	$ 109	$ 109
Investment Agreement [Member]
Issuance expenses paid	300	300
Best Efforts [Member]
Issuance expenses paid	686	686
Registered Direct [Member]
Issuance expenses paid	1,035	1,035
Warrant Exercise [Member]
Issuance expenses paid	$ 1,019	$ 1,019

General

General	6 Months Ended
	Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GENERAL	NOTE 1:- GENERAL a. ReWalk Robotics Ltd. (“RRL”, and together with its subsidiaries, the “Company”) was incorporated under the laws of the State of Israel on June 20, 2001 and commenced operations on the same date. b. RRL has two wholly-owned subsidiaries: (i) ReWalk Robotics Inc. (“RRI”) incorporated under the laws of Delaware on February 15, 2012 and (ii) ReWalk Robotics GMBH. (“RRG”) incorporated under the laws of Germany on January 14, 2013. c. The Company is designing, developing and commercializing robotic exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The Company has developed and is continuing to commercialize the ReWalk, an exoskeleton designed for individuals with paraplegia that uses our patented tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement. The ReWalk system consists of a light wearable brace support suit which integrates motors at the joints, rechargeable batteries, an array of sensors and a computer-based control system to power knee and hip movement. There are currently two types of ReWalk products: ReWalk Personal and ReWalk Rehabilitation. ReWalk Personal is designed for everyday use by individuals at home and in their communities and is custom-fitted for each user. ReWalk Rehabilitation is designed for the clinical rehabilitation environment where it provides individuals access to valuable exercise and therapy. Additionally, the Company has developed and started to commercialize the ReStore in June 2019. The ReStore is a powered, lightweight soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke. d. On March 27, 2019, the Board of Directors of the Company authorized a reverse share split of the Company’s issued and outstanding common shares at a ratio of 1-for-25, which became effective on April 1, 2019. At the effective time, every twenty-five shares of the Company’s common shares that were issued and outstanding were automatically combined into one issued and outstanding share, the par value per share of the ordinary shares changed to NIS 0.25. All authorized, issued and outstanding share and per share amounts contained in the accompanying Condensed Consolidated Financial Statements have been adjusted to reflect this reverse share split for all prior periods presented. All share and per share data included in these condensed consolidated financial statements give retroactive effect to the reverse stock split for all periods presented. e. The Company has an accumulated deficit in the total amount of approximately $162 million as of June 30, 2019 and negative cash flow from operations of $8 million, and further losses are anticipated in the development of its business. Those factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. The Company intends to finance operating costs over the next twelve months with existing cash on hand, reducing operating spend, and future issuances of equity and debt securities, or through a combination of the foregoing. However, the Company will need to seek additional sources of financing if the Company requires more funds than anticipated during the next 12 months or in later periods. The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business. The condensed consolidated financial statements for the three and six months ended June 30, 2019 do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern.

Unaudited Interim Condensed Con

Unaudited Interim Condensed Consolidated Financial Statements	6 Months Ended
	Jun. 30, 2019
Unaudited Interim Condensed Consolidated Financial Statements
UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	NOTE 2:- UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles and standards of the Public Company Accounting Oversight Board for interim financial information. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles in the United States for complete financial statements. In the opinion of management, the accompanying financial statements include all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the Company’s (i) consolidated financial position as of June 30, 2019, (ii) consolidated results of operations for the three and six months ended June 30, 2019 and (iii) consolidated statements of changes in shareholders’ equity (deficiency) (iv) consolidated cash flows for the six months ended June 30, 2019. The results for the three and six months periods ended June 30, 2019, as applicable, are not necessarily indicative of the results that may be expected for the year ending December 31, 2019.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 3:- SIGNIFICANT ACCOUNTING POLICIES a. Revenue Recognition The Company generates revenues from sales of products. The Company sells its products directly to end customers and through distributors. The Company sells its products to private individuals (who finance the purchases by themselves, through fundraising or reimbursement coverage from insurance companies), rehabilitation facilities and distributors. Disaggregation of Revenues Three Months Ended Six Months Ended 2019 2018 2019 2018 Units placed $ 772 $ 1,672 $ 2,246 $ 3,200 Spare parts and warranties 105 98 212 149 Total Revenues $ 877 $ 1,770 $ 2,458 $ 3,349 Units placed We currently offer three products: ReWalk Personal, ReWalk Rehabilitation units for Spinal Cord Injury (“SCI Products”) and ReStore soft suit exoskeleton for rehabilitation of individuals suffering from stroke. SCI Products are currently designed for everyday use by paraplegic individuals at home and in their communities, and is custom fitted for each user, as well as for use by paraplegia patients in the clinical rehabilitation environment, where it provides individuals access to valuable exercise and therapy. The ReStore is a powered, lightweight soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment. Units placed includes revenue from sales of SCI Products and ReStore. For SCI Products, we also offer a rent-to-purchase model in which we recognize revenue according to the agreed rental monthly fee. For units placed, we transfer control and recognize a sale when title has passed to our customer and rental revenue is recognized ratably according to the agreed rental monthly fee. Each unit placed is considered an independent, unbundled performance obligation. Spare parts and warranties Spare parts are sold to private individuals, rehabilitation facilities and distributors. For spare part sales, we transfer control and recognize a sale when title has passed to our customer. Each part sold is considered an independent, unbundled performance obligation. Warranties are classified as either assurance type or service type warranty. A warranty is considered an assurance type warranty if it provides the consumer with assurance that the product will function as intended for a limited period of time. In the beginning of 2018, we updated our service policy for SCI Products to include a five-year warranty compared to a period of two years that were included in the past for parts and services. The first two years are considered as assurance type warranty and the additional period is considered an extended service arrangement, which is a service type warranty. An assurance type warranty is not accounted for as separate performance obligations under the revenue model. A service type warranty is either sold with a unit or separately for units for which the warranty has expired. Revenue is then recognized ratably over the life of the warranty. The ReStore device is offered with two-year warranty which are considered as assurance type warranty. Contract balances June 30, December 31, 2019 2018 Trade receivable, net (1) $ 417 $ 758 Deferred revenues (1) (2) $ 870 $ 668 (1) Balance presented net of unrecognized revenues that were not yet collected. (2) $184 thousand of December 31, 2018 deferred revenues balance were recognized as revenues during the six months ended June 30, 2019. Revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts that have an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, is not material. The Company’s unfilled performance obligations as of June 30, 2019 and the estimated revenue expected to be recognized in the future related to the service type warranty amounts to $874 thousand, which is fulfilled over one to five years. b. New Accounting Pronouncements Recently Implemented Accounting Pronouncements In February 2016, the FASB issued Accounting Standard Update, or ASU, No. 2016-02, Leases (Topic 842), to enhance the transparency and comparability of financial reporting related to leasing arrangements. The Company adopted the standard effective January 1, 2019. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Prior to our adoption of ASU 2016-02, when our lease agreements contained rent payment relief and rent escalation clauses, we recorded a deferred rent asset or liability equal to the difference between the rent expense and the future minimum lease payments due. Operating leases are recognized on the balance sheet as right-of-use assets, current maturities of operating leases and noncurrent operating lease liabilities. The Company used the modified retrospective transition method, under which we applied the standard as a cumulative effect adjustment to each lease that had commenced as of the beginning of January 1, 2019 and did not apply the standard to comparative historical periods. In addition, the Company elected to apply the package of practical expedients permitted under the transition guidance, which among other things, allowed the Company to carry forward the historical lease classification. The Company has elected, as of the adoption date, not to reassess whether expired or existing contracts contain leases under the new definition of a lease, not to reassess the lease classification for expired or existing leases, and not to reassess whether previously capitalized initial direct costs would qualify for capitalization under ASC 842. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company recognizes the lease expense for such leases on a straight-line basis in the statement of operations over the lease term. As a result, the Company no longer recognizes deferred rent on the balance sheet. Upon adoption of this standard on January 1, 2019, the Company recorded right–of–use assets and corresponding lease liabilities of $2,099 and $2,249, respectively. As of June 30, 2019, the right–of–use assets and corresponding lease liabilities in the Company’s condensed consolidated balance sheets were $1,893 and $2,039, respectively. The adoption of this standard did not have a material impact on the Company’s condensed consolidated statements of operations or cash flows. See also note 5b - Lease commitment. Recent Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments and subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04 and ASU 2019-05, which amends the current approach to estimate credit losses on certain financial assets, including trade and other receivables. Generally, this amendment requires entities to establish a valuation allowance for the expected lifetime losses of these certain financial assets. Upon the initial recognition of such assets, which will be based on, among other things, historical information, current conditions, and reasonable supportable forecasts. Subsequent changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. Currently, U.S. GAAP requires entities to write down credit losses only when losses are probable and loss reversals are not permitted. The update is effective for the Company in the first quarter of 2020. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this standard will have on its consolidated financial statements and related disclosures. c. Concentrations of Credit Risks: Concentration of credit risk with respect to trade receivable is primarily limited to a customer to which the Company makes substantial sales. June 30, December 31, 2019 2018 Customer A 25 % * ) Customer B 25 % * ) Customer C 23 % * ) Customer D 20 % * ) Customer E * ) 28 % Customer F * ) 15 % Customer G * ) 14 % Customer H * ) 13 % Customer I * ) 12 % *) Less than 10% The Company’s trade receivables are geographically diversified and derived primarily from sales to customers in various countries, mainly in the United States and Europe. Concentration of credit risk with respect to trade receivables is limited by credit limits, ongoing credit evaluation and account monitoring procedures. The Company performs ongoing credit evaluations of its distributors based upon a specific review of all significant outstanding invoices. The Company writes off receivables when they are deemed uncollectible and having exhausted all collection efforts. As of June 30, 2019 and December 31, 2018 trade receivables are presented net of allowance for doubtful accounts in the amount of $31 thousand and $32 thousand, respectively, and net of sales return reserve of $86 thousand and $105 thousand as of June 30, 2019 and December 31, 2018, respectively. d. Warranty provision The Company provided a two-year standard warranty for its SCI products. In the beginning of 2018, we updated our service policy for new SCI Products sold to include a five-year warranty. ReStore service policy includes two-year warranty. The Company determined that the first two years of warranty is an assurance-type warranty and records a provision for the estimated cost to repair or replace products under warranty at the time of sale. Factors that affect the Company’s warranty reserve include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair. US Dollars in thousands Balance at December 31, 2018 $ 304 Provision 105 Usage (152 ) Balance at June 30, 2019 $ 257

Inventories

Inventories	6 Months Ended
	Jun. 30, 2019
Inventory Disclosure [Abstract]
INVENTORIES	NOTE 4:- INVENTORIES The components of inventories are as follows (in thousands): June 30, December 31, 2019 2018 Finished products $ 2,310 $ 2,240 Raw materials 351 — $ 2,661 $ 2,240

Commitments and Contingent Liab

Commitments and Contingent Liabilities	6 Months Ended
	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENT LIABILITIES	NOTE 5:- COMMITMENTS AND CONTINGENT LIABILITIES a. Purchase commitments: The Company has contractual obligations to purchase goods from its contract manufacturer as well as raw materials from different vendors. Purchase obligations do not include contracts that may be canceled without penalty. As of June 30, 2019, non-cancelable outstanding obligations to the Company’s contract manufacturer and raw material vendors amounted to approximately $1.35 million. b. Operating lease commitment: (i) The Company operates from leased facilities in Israel, the United States and Germany. These leases expire between 2019 and 2023. A portion of our facilities leases is generally subject to annual changes in the Consumer Price Index (CPI). The changes to the CPI are treated as variable lease payments and recognized in the period in which the obligation for those payments was incurred. (ii) RRL and RRG lease cars for their employees under cancelable operating lease agreements expiring at various dates in between 2019 and 2022. A subset of our cars leases is considered variable. The variable lease payments for such cars leases are based on actual mileage incurred at the stated contractual rate. RRL and RRG have an option to be released from these agreements, which may result in penalties in a maximum amount of approximately $44 thousand as of June 30, 2019. The Company’s future lease payments for its facilities and cars, which are presented as current maturities of operating leases and non-current operating leases liabilities on the Company’s condensed consolidated balance sheets as of June 30, 2019 are as follows (in thousands): 2019 $ 345 2020 638 2021 613 2022 566 2023 439 Total lease payments 2,601 Less: imputed interest (562 ) Present value of future lease payments 2,039 Less: current maturities of operating leases (635 ) Non-current operating leases $ 1,404 Weighted-average remaining lease term (in years) 3.48 Weighted-average discount rate 12.5 % Lease expense under the Company’s operating leases were $180 thousand and $187 thousand for the three months ended June 30, 2019 and 2018, respectively. For the six months ended June 30, 2019 and 2018 the lease expense were $360 thousand and $375 thousand, respectively. c. Royalties: The Company’s research and development efforts are financed, in part, through funding from the Israel Innovation Authority (the “IIA”) and Israel-U.S. Binational Industrial Research and Development Foundation (the “BIRD”). Since the Company’s inception through June 30, 2019, the Company received funding from the IIA and BIRD in the total amount of $1.97 million and $500 thousand, respectively. Out of the $1.97 million in funding from the IIA, a total amount of $1.57 million were royalty bearing grants (as of June 30, 2019, the Company paid royalties to the IIA in the total amount of $50 thousand), while a total amount of $400 thousand was received in consideration of 209 convertible preferred A shares, which converted after our initial public offering in September 2014 into ordinary shares in a conversion ratio of 1 to 1. The Company is obligated to pay royalties to the IIA, amounting to 3%-3.5% of the sales of the products and other related revenues generated from such projects, up to 100% of the grants received. The royalty payment obligations also bear interest at the LIBOR rate. The obligation to pay these royalties is contingent on actual sales of the applicable products and in the absence of such sales, no payment is required. The Company was obligated to pay royalties to BIRD amounting to 5% of the sales of the products and other related revenues generated from such projects, up to 150% of the grants received. Additionally, the License Agreement requires the Company to pay Harvard royalties on net sales, See note 6 below for more information about the Collaboration Agreement and the License Agreement. During the three and six months ended June 30, 2019, $2 and $5 thousand, respectively, were recorded as royalties expenses in cost of revenues. No royalties expenses were recorded during the three and six months ended June 30, 2018. As of June 30, 2019, the contingent liability to the IIA amounted to $1.5 million. The Israeli Research and Development Law provides that know-how developed under an approved research and development program may not be transferred to third parties without the approval of the IIA. Such approval is not required for the sale or export of any products resulting from such research or development. The IIA, under special circumstances, may approve the transfer of IIA-funded know-how outside Israel, in the following cases: (a) the grant recipient pays to the IIA a portion of the sale price paid in consideration for such IIA-funded know-how or in consideration for the sale of the grant recipient itself, as the case may be, which portion will not exceed six times the amount of the grants received plus interest (or three times the amount of the grant received plus interest, in the event that the recipient of the know-how has committed to retain the research and development activities of the grant recipient in Israel after the transfer); (b) the grant recipient receives know-how from a third party in exchange for its IIA-funded know-how; (c) such transfer of IIA-funded know-how arises in connection with certain types of cooperation in research and development activities; or (d) if such transfer of know-how arises in connection with a liquidation by reason of insolvency or receivership of the grant recipient. d. Liens: As discussed in Note 6 to the Company’s audited consolidated financial statements in its annual report on Form 10-K for the fiscal year ended December 31, 2018 (the “2018 Form 10-K”), the Company is party to a loan agreement, as amended (the “Loan Agreement”), with Kreos Capital V (Expert Fund) Limited (“Kreos”), pursuant to which Kreos extended a $20 million line of credit to the Company. In connection with the Loan Agreement, the Company granted Kreos a first priority security interest over all of its assets, including intellectual property and equity interests in its subsidiaries, subject to certain permitted security interests. The Company’s other long-term assets in the amount of $810 thousand have been pledged to third parties as a security in respect to lease agreements . e. Legal Claims: Occasionally the Company is involved in various claims, lawsuits, regulatory examinations, investigations and other legal matters arising, for the most part, in the ordinary course of business. The outcome of litigation and other legal matters is inherently uncertain. In making a determination regarding accruals, using available information, the Company evaluates the likelihood of an unfavorable outcome in legal or regulatory proceedings to which the Company is a party and records a loss contingency when it is probable a liability has been incurred and the amount of the loss can be reasonably estimated. Where the Company determines an unfavorable outcome is not probable or reasonably estimable, the Company does not accrue for any potential litigation loss. These subjective determinations are based on the status of such legal or regulatory proceedings, the merits of the Company’s defenses and consultation with legal counsel. Actual outcomes of these legal and regulatory proceedings may materially differ from the Company’s current estimates. It is possible that resolution of one or more of the legal matters currently pending or threatened could result in losses material to the Company’s consolidated results of operations, liquidity or financial condition. As set forth below, between September 2016 and January 2017, eight putative class actions on behalf of alleged shareholders that purchased or acquired the Company’s ordinary shares pursuant and/or traceable to the registration statement on Form F-1 (File No. 333-197344) used in connection with the Company’s initial public offering (the “IPO”), were commenced in the following courts: (i) the Superior Court of the State of California, County of San Mateo; (ii) the Superior Court of the Commonwealth of Massachusetts, Suffolk County; (iii) the United States District Court for the Northern District of California; and (iv) the United States District Court for the District of Massachusetts. As of May 3, 2019, seven have been dismissed and one has been partially dismissed. The actions involved or involve claims under various sections of the Securities Act of 1933, as amended (the “Securities Act”) against the Company, certain of the Company’s current and former directors and officers, the underwriters of the IPO and certain other defendants. The four actions commenced in the Superior Court of the State of California, County of San Mateo were dismissed in January 2017 for lack of personal jurisdiction, and the action commenced in the United States District Court for the Northern District of California was voluntarily dismissed in March 2017. Additionally, the two actions commenced in the Superior Court of the Commonwealth of Massachusetts, Suffolk County, or the Superior Court, were consolidated in December 2017, and voluntarily dismissed with prejudice in November 2018, after the District Court for the District of Massachusetts partially dismissed the related claims in that court and the parties in the Superior Court entered a stipulation of dismissal with prejudice. The action commenced in the United States District Court for the District of Massachusetts (the “District Court”), alleging violations of Sections 11 and 15 of the Securities Act and Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), was partially dismissed on August 23, 2018. In particular, the District Court granted the motion to dismiss the claims under Sections 11 and 15 of the Securities Act, finding that the plaintiff failed to plead a false or misleading statement in the IPO registration statement. The District Court did not address the claims under Sections 10(b) and 20(a) of the Exchange Act because, as a result of the dismissal of the claims under the Securities Act, the lead plaintiff lacked standing to pursue those claims. Because the action in the District Court was styled as a class action, the District Court permitted the plaintiff to file a supplemental memorandum concerning standing or a motion to appoint a substitute or supplemental plaintiff. On September 10, 2018, the plaintiff sought leave to amend his complaint to add a new plaintiff that purportedly has standing to pursue Exchange Act claims, and the Company opposed the motion to amend on September 24, 2018. On May 16, 2019, the court denied the plaintiff’s motion to amend and the complaint was dismissed. Thereafter, the plaintiff timely appealed to the United States Court of Appeals for the First Circuit. The plaintiff’s appellate brief is due on August 26, 2019 and the Company’s opposition is due on September 25, 2019. Based on information currently available and the current stage of the litigation, we are unable to reasonably estimate a possible loss or range of possible losses, if any, with regard to the remaining lawsuit in the District Court; therefore, no litigation reserve has been recorded in our condensed consolidated balance sheets as of June 30, 2019. We will continue to evaluate information as it becomes known and will record an estimate for losses at the time or times if and when it is probable that a loss will be incurred and the amount of the loss is reasonably estimable.

Research Collaboration Agreemen

Research Collaboration Agreement and License Agreement	6 Months Ended
	Jun. 30, 2019
Research and Development [Abstract]
RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT	NOTE 6:- RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT On May 16, 2016, the Company entered into a Research Collaboration Agreement and an Exclusive License Agreement with Harvard College. The Research Collaboration Agreement was amended on May 1, 2017 and April 1, 2018 (as amended, the “Collaboration Agreement”), and the Exclusive License Agreement was amended on April 1, 2018 (as amended, the “License Agreement”), to extend the term of the Collaboration Agreement by one year to May 16, 2022 and reallocate the Company’s quarterly installment payments to Harvard through such date, and to make certain technical changes. Under the Collaboration Agreement, Harvard and the Company have agreed to collaborate on research regarding the development of lightweight “soft suit” exoskeleton system technologies for lower limb disabilities, which are intended to treat stroke, multiple sclerosis, mobility limitations for the elderly and other medical applications. The Company has committed to pay in quarterly installments for the funding of this research, subject to a minimum funding commitment under applicable circumstances. The Collaboration Agreement will expire on May 16, 2022. Under the License Agreement, Harvard has granted the Company an exclusive, worldwide royalty-bearing license under certain patents of Harvard relating to lightweight “soft suit” exoskeleton system technologies for lower limb disabilities, a royalty-free license under certain related know-how and the option to obtain a license under certain inventions conceived under the joint research collaboration. The License Agreement requires the Company to pay Harvard an upfront fee, reimbursements for expenses that Harvard incurred in connection with the licensed patents, royalties on net sales and several milestone payments contingent upon the achievement of certain product development and commercialization milestones. The License Agreement will continue in full force and effect until the expiration of the last-to-expire valid claim of the licensed patents. As of June 30, 2019, the Company achieved three of the milestones which represent all development milestones under the License Agreement. The Company continues to evaluate the likelihood that the other milestones will be achieved on a quarterly basis. The Company’s total payment obligation under the Collaboration Agreement and the License Agreement is $7.1 million, some of which is subject to a minimum funding commitment under applicable circumstances as indicated above. The Company has recorded expenses in the amount of $868 thousand and $1,112 thousand which are part of the total payment obligation indicated above, as research and development expenses related to the License Agreement and to the Collaboration Agreement for the three and six months ended June 30, 2019, respectively. No withholding tax was deducted from the Company’s payments to Harvard in respect of the Collaboration Agreement and the License Agreement since this is not taxable income in Israel in accordance with Section 170 of the Israel Income Tax Ordinance 1961-5721.

Shareholders' Equity

Shareholders' Equity	6 Months Ended
	Jun. 30, 2019
Equity [Abstract]
SHAREHOLDERS' EQUITY	NOTE 7:- SHAREHOLDERS' EQUITY a. Reverse share split: On March 27, 2019, the Company's shareholders approved (i) a reverse share split within a range of 1:8 to 1:32, to be effective at the ratio and on a date to be determined by the Board of Directors, and (ii) amendments to the Company's Articles of Association authorizing an increase in the Company's authorized share capital (and corresponding authorized number of ordinary shares, proportionally adjusting such number for the reverse share split) by up to NIS 17.5 million. Following the shareholder approval, an authorized committee of the Board of Directors of the Company approved a one-for-twenty-five reverse share split of the Company's ordinary shares, and the Company filed the Third Amended and Restated Articles of Association of the Company with the Registrar of Companies of the State of Israel to effect the reverse share split and to increase the Company's authorized share capital after the effect of the reverse share split. The reverse share split became effective on April 1, 2019. Additionally, effective at the same time, the total number of ordinary shares the Company is authorized to issue changed from 250,000,000 shares to 60,000,000 shares, the par value per share of the ordinary shares changed to NIS 0.25 and the authorized share capital of the Company changed from NIS 2,500,000 to NIS 15,000,000. All share and per share data included in these condensed consolidated financial statements, for periods before the three months ended June 30, 2019, give retroactive effect to the reverse stock split. Upon the effectiveness of the reverse share split, every twenty-five shares were automatically combined and converted into one ordinary share. Appropriate adjustments were also made to all outstanding derivative securities of the Company, including all outstanding equity awards and warrants. No fractional shares were issued in connection with the reverse share split. Instead, all fractional shares (including shares underlying outstanding equity awards and warrants) were rounded down to the nearest whole number. b. Share option plans: As of June 30, 2019, and December 31, 2018, the Company had reserved 3,287 and 52,298 ordinary shares, respectively, for issuance to the Company's and its affiliates' respective employees, directors, officers and consultants pursuant to equity awards granted under the Company's 2014 Incentive Compensation Plan (the "2014 Plan"). Options to purchase ordinary shares generally vest over four years, with certain options to non-employee directors vesting quarterly over one year. Any option that is forfeited or canceled before expiration becomes available for future grants under the 2014 Plan. The fair value for options granted during the six months ended June 30, 2019 and 2018 was estimated at the date of the grant using a Black-Scholes-Merton option pricing model with the following assumptions: Six Months Ended 2019 2018 Expected volatility 57.5 % 57.19 - 61.12 % Risk-free rate 2.22 % 2.74% - 2.83 % Dividend yield — % — % Expected term (in years) 6.11 6.11 Share price $ 5.37 $ 26.88 - $28.75 The fair value of restricted share units ("RSUs") granted is determined based on the price of the Company's ordinary shares on the date of grant. A summary of employee share options activity during the six months ended June 30, 2019 is as follows: Number Average exercise price Average remaining contractual life (in years) Aggregate intrinsic value (in thousands) Options outstanding at the beginning of the period 72,655 $ 47.70 6.37 $ 114 Granted 12,425 5.37 Exercised — — Forfeited (5,371 ) 45.93 Options outstanding at the end of the period 79,709 $ 41.19 6.80 $ 393 Options exercisable at the end of the period 43,868 $ 56.49 4.96 $ — A summary of employee RSUs activity during the six months ended June 30, 2019 is as follows: Number of shares underlying outstanding RSUs Weighted Unvested RSUs at the beginning of the period 26,093 $ 48.78 Granted 87,436 4.69 Vested (16,656 ) 9.82 Forfeited (6,599 ) 17 Unvested RSUs at the end of the period 90,274 $ 37.49 The weighted average grant date fair value of options granted during the six months ended June 30, 2019 and 2018 were $2.98 and $15.25, respectively. The weighted average grant date fair value of RSUs granted during the six months ended June 30, 2019 and 2018 were $4.69 and $27.50, respectively. The aggregate intrinsic value in the table above represents the total intrinsic value that would have been received by the option holders had all option holders that hold options with positive intrinsic value exercised their options on the last date of the exercise period. No options were exercised during the six months ended June 30, 2019 and 2018. As of June 30, 2019, there were $1.5 million of total unrecognized compensation costs related to non-vested share-based compensation arrangements granted under the Company's 2012 Equity Incentive Plan and its 2014 Plan. This cost is expected to be recognized over a period of approximately 1.88 years. The number of options and RSUs outstanding as of June 30, 2019 is set forth below, with options separated by range of exercise price. Range of exercise price Options and RSUs outstanding as of Weighted average remaining contractual life (years) (1) Options Weighted average remaining contractual life (years) (1) RSUs only 90,274 — — — $5.37 12,425 9.75 — — $20.42 - $33.75 39,220 6.85 19,570 4.86 $37.14 - $38.75 12,740 4.44 12,740 4.44 $50 - $52.5 11,395 6.20 7,697 5.36 $182.5 - $524.25 3,929 6.40 3,861 6.40 169,983 6.80 43,868 4.96 (1) Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term. c. Share-based awards to non-employee consultants: As of June 30, 2019, there are no outstanding options or RSUs held by non-employee consultants. d. Warrants to purchase ordinary shares: The following table summarizes information about warrants outstanding and exercisable as of June 30, 2019: Issuance date Warrants Exercise price per warrant Warrants outstanding and exercisable Contractual (number) (number) December 31, 2015 (1) 4,771 $ 7.500 4,771 See footnote (1) November 1, 2016 (2) 97,496 $ 118.750 97,496 November 1, 2021 December 28, 2016 (3) 1,908 $ 7.500 1,908 See footnote (1) November 20, 2018 (4) 126,839 $ 7.500 126,839 November 20, 2023 November 20, 2018 (5) 106,680 $ 9.375 106,680 November 15, 2023 February 25, 2019 (6) 45,600 $ 7.187 45,600 February 21, 2024 April 5, 2019 (7) 408,457 $ 5.140 408,457 October 7, 2024 April 5, 2019 (8) 49,015 $ 6.503 49,015 April 3, 2024 June 5, 2019 and June 6, 2019 (9) 1,464,665 $ 7.500 1,464,665 June 5, 2024 June 5, 2019 (10) 87,880 $ 9.375 87,880 June 5, 2024 June 12, 2019 (11) 416,667 $ 6.000 416,667 December 12, 2024 June 10, 2019 (12) 50,000 $ 7.500 50,000 June 10, 2024 2,859,978 2,859,978 (1) Represents warrants for ordinary shares issuable upon an exercise price of $7.5 per share, which were granted on December 31, 2015 to Kreos Capital V (Expert) Fund Limited, or Kreos, in connection with a loan made by Kreos to us and are currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of us with or into, or the sale or license of all or substantially all the assets or shares of us to, any other entity or person, other than a wholly-owned subsidiary of us, excluding any transaction in which our shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of June 30, 2019. (2) Represents warrants issued as part of our follow-on offering in November 2016. At any time, the board of directors may reduce the exercise price of the warrants to any amount and for any period of time it deems appropriate. (3) Represents common warrants that were issued as part of the $8.0 million drawdown under the Loan Agreement which occurred on December 28, 2016. See footnote 1 for exercisability terms. (4) Represents common warrants that were issued as part of our follow-on offering in November 2018. As of June 30, 2019, warrants to purchase an aggregate 1,651,537 ordinary shares had been exercised. (5) Represents common warrants that were issued to the underwriters as compensation for their role in our follow-on offering in November 2018. (6) Represents warrants that were issued to the exclusive placement agent as compensation for its role in our follow-on offering in February 2019. (7) Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in April 2019. (8) Represents warrants that were issued to the placement agent as compensation for its role in our April 2019 registered direct offering. (9) Represents warrants that were issued to certain institutional investors in a warrant exercise agreement on June 5, 2019 and June 6, 2019, respectively. (10) Represents warrants that were issued to the placement agent as compensation for its role in our June 2019 warrant exercise agreement and concurrent private placement of warrants. (11) Represents warrants that were issued to certain institutional investors in a warrant exercise agreement in June 2019. (12) Represents warrants that were issued to the placement agent as compensation for its role in our June 2019 registered direct offering and concurrent private placement of warrants. e. Share-based compensation expense for employees and non-employees: The Company recognized non-cash share-based compensation expense for both employees and non-employees in the condensed consolidated statements of operations as follows (in thousands): Six Months Ended 2019 2018 Cost of revenues $ 7 $ 7 Research and development, net 124 203 Sales and marketing 126 300 General and administrative 376 1,309 Total $ 633 $ 1,819 f. Equity raise: 1. At-the-market offering program: On May 10, 2016, the Company entered into an equity distribution agreement (the "Equity Distribution Agreement") with Piper Jaffray & Co. ("Piper Jaffray"), as amended on May 9, 2019, pursuant to which it may offer and sell, from time to time, ordinary shares having an aggregate offering price of up to $25 million, through Piper Jaffray acting as its agent. Subject to the terms and conditions of the Equity Distribution Agreement, Piper Jaffray will use its commercially reasonable efforts to sell on the Company's behalf all of the ordinary shares requested to be sold by the Company, consistent with its normal trading and sales practices. Piper Jaffray may also act as principal in the sale of ordinary shares under the Equity Distribution Agreement. Sales may be made under the Company's shelf registration statement on Form S-3, which was declared effective by the SEC on May 9, 2016, or the Company's shelf registration statement on Form S-3, which was declared effective by the SEC on May 23, 2019 (the "Form S-3"), in what may be deemed "at-the-market" equity offerings as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the "ATM Offering Program"). Sales may be made directly on or through the NASDAQ Capital Market, the existing trading market for the Company's ordinary shares, to or through a market maker other than on an exchange or otherwise, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, and/or any other method permitted by law, including in privately negotiated transactions. Piper Jaffray is entitled to compensation at a fixed commission rate of 3.0% of the gross sales price per share sold through it as agent under the Equity Distribution Agreement. Where Piper Jaffray acts as principal in the sale of ordinary shares under the Equity Distribution Agreement, such rate of compensation will not apply, but in no event will the total compensation of Piper Jaffray, when combined with the reimbursement of Piper Jaffray for the out-of-pocket fees and disbursements of its legal counsel, exceed 8.0% of the gross proceeds received from the sale of the ordinary shares. The Company is not required to sell any of its ordinary shares at any time. From the inception of the ATM Offering Program in May 2016 until June 30, 2019, the Company had sold 302,092 ordinary shares under the ATM Offering Program for gross proceeds of $15.7 million and net proceeds to the Company of $14.5 million (after commissions, fees and expenses). Additionally, as of that date, the Company had paid Piper Jaffray compensation for the fixed commission rate of 3.0% in the aggregated amount of $471 thousand and had incurred total expenses of approximately $1,171 thousand in connection with the ATM Offering Program. 2. Follow-on offerings In November 2018, the Company entered into an underwriting agreement with H.C. Wainwright & Co., LLC ("H.C. Wainwright"), in connection with the Company's follow-on public offering of 496,040 units, each consisting of one ordinary share and one common warrant to purchase one ordinary share with an exercise price of $7.5 per warrant. Each unit was sold to the public at a price of $7.50 per unit. On November 18, 2018, H.C. Wainwright exercised in full its option to purchase 231,964 ordinary shares for $7.25 per share and/or common warrants to purchase up to an additional 231,964 ordinary shares for $0.25 per warrant. Additionally, the Company issued and sold 1,050,372 pre-funded units at a price to the public of $7.25 per unit. Each unit containing one pre-funded warrant with an exercise price of $0.25 per share and one warrant to purchase one ordinary share with an exercise price of $7.50 per warrant. The total gross proceeds received from the November 2018 follow-on public offering, before deducting commissions, discounts and expenses, were $13.1 million (including proceeds from the exercise of 90,691 pre-funded warrants at the closing of the offering). As of December 31, 2018, additional pre-funded warrants to purchase an aggregate 562,466 ordinary shares had been exercised, for additional proceeds of $140,617. During the three months ended March 31, 2019 additional pre-funded warrants and warrants to purchase an aggregate 119,881 ordinary shares had been exercised, for additional proceeds of $107,303. As compensation for their role in the offering, the Company also issued to the Underwriters warrants to purchase up to 106,680 ordinary shares, which became immediately exercisable starting on November 20, 2018 until November 15, 2023 at $9.375 per share. In February 2019, the Company entered into an exclusive placement agent agreement with H.C. Wainwright, on a reasonable best-efforts basis in connection with a public offering of 760,000 ordinary shares at a price of $5.75 per share. The total gross proceeds received from the February 2019 follow-on public offering, before deducting commissions, discounts and expenses, were $4.37 million. The Company also issued to H.C Wainwright and/or its designees warrants to purchase up to 45,600 ordinary shares, which are immediately exercisable starting on February 25, 2019 until February 21, 2024 at $7.1875 per share. In April 2019, the Company entered into securities purchase agreements with certain institutional purchasers whereby the Company issued 816,914 ordinary shares at $5.2025 per ordinary share and warrants to purchase up to 408,457 ordinary shares with an exercise price of $5.14 per share, exercisable from April 5, 2019 until October 7, 2024, in a private placement that took place concurrently with the Company's registered direct offering of ordinary shares in April 2019. Additionally the Company issued warrants to purchase up to 49,015 ordinary shares, with an exercise price of $6.503125 per share, exercisable from April 5, 2019 until April 3, 2024, to representatives of H.C. Wainwright as compensation for its role as the placement agent in our April 2019 registered direct offering and concurrent private placement of warrants. On June 5, 2019 and June 6, 2019, the Company entered into warrant exercise agreements with certain institutional investors whereby the Company issued warrants to purchase up to 1,464,665 ordinary shares with an exercise price of $7.50 per share, exercisable from June 5, 2019 or June 6, 2019 until June 5, 2024 or June 6, 2024, respectively. Additionally, the Company issued warrants to purchase up to 87,880 ordinary shares, with an exercise price of $9.375 per share, exercisable from June 5, 2019 until June 5, 2024, to certain representatives of H.C. Wainwright as compensation for its role as the placement agent in our June 2019 warrant exercise agreement and concurrent private placement of warrants. On June 12, 2019, the Company entered into a purchase agreement with certain institutional investors for the issuance and sale of 833,334 ordinary shares, par value NIS 0.25 per share at $6.00 per ordinary share and warrants to purchase up to 416,667 ordinary shares with an exercise price of $6.00 per share, exercisable from June 12, 2019 until December 12, 2024, in a private placement that took place concurrently with our registered direct offering of ordinary shares in June 2019. Additionally, the Company issued warrants to purchase up to 50,000 ordinary shares, with an exercise price of $7.50 per share, exercisable from June 12, 2019 until June 10, 2024, to certain representatives of H.C. Wainwright as compensation for its role as the placement agent in our June 2019 registered direct offering and concurrent private placement of warrants. 3. Investment agreement On March 6, 2018, the Company entered into an investment agreement with Timwell Corporation Limited, a Hong Kong corporation ("Timwell"), as amended on May 15, 2018 (the "Investment Agreement"), pursuant to which the Company agreed to issue to Timwell, in three different tranches, an aggregate of 640,000 ordinary shares in return for aggregate gross proceeds of $20 million. The closing of each tranche is subject to certain closing conditions. The closing of the first tranche (the "First Tranche Closing") took place on May 15, 2018, upon which Timwell received 160,000 ordinary shares for an aggregate purchase price of $5,000,000, and Timwell and the Company signed a registration rights agreement in the form attached to the Investment Agreement. The net aggregate proceeds of the First Tranche Closing after deducting fees and other related expenses in the amount of approximately $705 thousands were approximately $4.3 million. The remaining investment is to occur in two tranches, including $10 million for the issuance to Timwell of 320,000 ordinary shares (the "Second Tranche") and $5 million for the issuance to Timwell of 160,000 ordinary shares (the "Third Tranch"). The closing of the second and third tranches is subject to specified closing conditions, including, with respect to the second tranche, the signing of a license agreement and a supply agreement and the formation of the China JV (the "China JV") based on the JV Framework Agreement, and, with respect to the third tranche, the successful production of certain ReWalk products by the China JV. The second tranche closing was initially expected to occur by July 1, 2018 and the third tranche closing was initially expected to occur by December 31, 2018 and no later than April 1, 2019. In light of the positions taken by Timwell during the negotiations on definitive joint venture and license agreements, we no longer believe that agreement can be reached on the basis of the original understandings reflected in our Investment Agreement with Timwell. We are currently in discussion with RealCan, Timwell's affiliate, on alternative pathways that will allow us to commercialize our products in China through RealCan and its affiliates, and also provide for RealCan or an affiliate to invest in us. While we currently intend to continue pursuing negotiations on this modification, due to the various delays in the process and other barriers to closing, there is a significant risk that we will not reach agreement with RealCan on a modification of the original agreement. As we continue to view China as a market with key opportunities for products designed for stroke patients, we continue to evaluate potential relationships with other groups to penetrate the Chinese market. In May 2018, the Company entered into a fee and release agreement with Canaccord Genuity LLC ("Canaccord Genuity") requiring the Company to pay to Canaccord Genuity, in connection with a settlement, in addition to certain cash amounts, (i) $125 thousand in ordinary shares of the Company after the First Tranche Closing of the Timwell transaction and (ii) $225 thousand in ordinary shares of the Company after the closing of the Second Tranche of the Timwell transaction (or such lower amount if the Second Tranche Closing is less than $10.0 million). The price per share used for calculation of the number of ordinary shares issued by the Company to Canaccord Genuity is based on the volume weighted average price of the Company's ordinary shares as reported on the Nasdaq Capital Market for the five consecutive trading days prior to the date of issuance. The Company is also obligated to pay $100 thousand in cash following the closing of the Third Tranche of $5.0 million (or such lower amount if the Third Tranche Closing is less than $5.0 million). Following the First Tranche Closing in May 15, 2018, the Company issued 4,715 ordinary shares to Canaccord Genuity.

Financial Expenses, Net

Financial Expenses, Net	6 Months Ended
	Jun. 30, 2019
Other Income and Expenses [Abstract]
FINANCIAL EXPENSES, NET	NOTE 8:- FINANCIAL EXPENSES, NET The components of financial expenses, net were as follows (in thousands): Three Months Ended Six Months Ended 2019 2018 2019 2018 Foreign currency transactions and other $ (43 ) $ 58 $ (40 ) $ 39 Financial expenses related to loan agreement with Kreos 386 455 790 950 Bank commissions 10 9 21 18 $ 353 $ 522 $ 771 $ 1,007

Geographic Information and Majo

Geographic Information and Major Customer and Product Data	6 Months Ended
	Jun. 30, 2019
Segment Reporting [Abstract]
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA	NOTE 9:- GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA Summary information about geographic areas: ASC 280, "Segment Reporting" establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company manages its business on the basis of one reportable segment, and derives revenues from selling units and services (see Note 1 for a brief description of the Company's business). The following is a summary of revenues within geographic areas: Three Months Ended Six Months Ended 2019 2018 2019 2018 Revenues based on customer's location : Israel $ 2 $ — $ 2 $ — United States 426 1,091 923 2,269 Europe 418 673 1,497 1,014 Asia-Pacific 31 6 36 8 Latin America — — — 58 Total revenues $ 877 $ 1,770 $ 2,458 $ 3,349 June 30, December 31, 2019 2018 Long-lived assets by geographic region (*): Israel $ 181 $ 206 United States 236 330 Germany 36 90 $ 453 $ 626 (*) Long-lived assets are comprised of property and equipment, net. Six Months Ended 2019 2018 Major customer data as a percentage of total revenues: Customer A 17.1 % 46.4 %

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Revenue Recognition	a. Revenue Recognition The Company generates revenues from sales of products. The Company sells its products directly to end customers and through distributors. The Company sells its products to private individuals (who finance the purchases by themselves, through fundraising or reimbursement coverage from insurance companies), rehabilitation facilities and distributors. Disaggregation of Revenues Three Months Ended Six Months Ended 2019 2018 2019 2018 Units placed $ 772 $ 1,672 $ 2,246 $ 3,200 Spare parts and warranties 105 98 212 149 Total Revenues $ 877 $ 1,770 $ 2,458 $ 3,349 Units placed We currently offer three products: ReWalk Personal, ReWalk Rehabilitation units for Spinal Cord Injury (“SCI Products”) and ReStore soft suit exoskeleton for rehabilitation of individuals suffering from stroke. SCI Products are currently designed for everyday use by paraplegic individuals at home and in their communities, and is custom fitted for each user, as well as for use by paraplegia patients in the clinical rehabilitation environment, where it provides individuals access to valuable exercise and therapy. The ReStore is a powered, lightweight soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment. Units placed includes revenue from sales of SCI Products and ReStore. For SCI Products, we also offer a rent-to-purchase model in which we recognize revenue according to the agreed rental monthly fee. For units placed, we transfer control and recognize a sale when title has passed to our customer and rental revenue is recognized ratably according to the agreed rental monthly fee. Each unit placed is considered an independent, unbundled performance obligation. Spare parts and warranties Spare parts are sold to private individuals, rehabilitation facilities and distributors. For spare part sales, we transfer control and recognize a sale when title has passed to our customer. Each part sold is considered an independent, unbundled performance obligation. Warranties are classified as either assurance type or service type warranty. A warranty is considered an assurance type warranty if it provides the consumer with assurance that the product will function as intended for a limited period of time. In the beginning of 2018, we updated our service policy for SCI Products to include a five-year warranty compared to a period of two years that were included in the past for parts and services. The first two years are considered as assurance type warranty and the additional period is considered an extended service arrangement, which is a service type warranty. An assurance type warranty is not accounted for as separate performance obligations under the revenue model. A service type warranty is either sold with a unit or separately for units for which the warranty has expired. Revenue is then recognized ratably over the life of the warranty. The ReStore device is offered with two-year warranty which are considered as assurance type warranty. Contract balances June 30, December 31, 2019 2018 Trade receivable, net (1) $ 417 $ 758 Deferred revenues (1) (2) $ 870 $ 668 (1) Balance presented net of unrecognized revenues that were not yet collected. (2) $184 thousand of December 31, 2018 deferred revenues balance were recognized as revenues during the six months ended June 30, 2019. Revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts that have an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, is not material. The Company’s unfilled performance obligations as of June 30, 2019 and the estimated revenue expected to be recognized in the future related to the service type warranty amounts to $874 thousand, which is fulfilled over one to five years.
New Accounting Pronouncements	b. New Accounting Pronouncements Recently Implemented Accounting Pronouncements In February 2016, the FASB issued Accounting Standard Update, or ASU, No. 2016-02, Leases (Topic 842), to enhance the transparency and comparability of financial reporting related to leasing arrangements. The Company adopted the standard effective January 1, 2019. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Prior to our adoption of ASU 2016-02, when our lease agreements contained rent payment relief and rent escalation clauses, we recorded a deferred rent asset or liability equal to the difference between the rent expense and the future minimum lease payments due. Operating leases are recognized on the balance sheet as right-of-use assets, current maturities of operating leases and noncurrent operating lease liabilities. The Company used the modified retrospective transition method, under which we applied the standard as a cumulative effect adjustment to each lease that had commenced as of the beginning of January 1, 2019 and did not apply the standard to comparative historical periods. In addition, the Company elected to apply the package of practical expedients permitted under the transition guidance, which among other things, allowed the Company to carry forward the historical lease classification. The Company has elected, as of the adoption date, not to reassess whether expired or existing contracts contain leases under the new definition of a lease, not to reassess the lease classification for expired or existing leases, and not to reassess whether previously capitalized initial direct costs would qualify for capitalization under ASC 842. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company recognizes the lease expense for such leases on a straight-line basis in the statement of operations over the lease term. As a result, the Company no longer recognizes deferred rent on the balance sheet. Upon adoption of this standard on January 1, 2019, the Company recorded right–of–use assets and corresponding lease liabilities of $2,099 and $2,249, respectively. As of June 30, 2019, the right–of–use assets and corresponding lease liabilities in the Company’s condensed consolidated balance sheets were $1,893 and $2,039, respectively. The adoption of this standard did not have a material impact on the Company’s condensed consolidated statements of operations or cash flows. See also note 5b - Lease commitment. Recent Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments and subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04 and ASU 2019-05, which amends the current approach to estimate credit losses on certain financial assets, including trade and other receivables. Generally, this amendment requires entities to establish a valuation allowance for the expected lifetime losses of these certain financial assets. Upon the initial recognition of such assets, which will be based on, among other things, historical information, current conditions, and reasonable supportable forecasts. Subsequent changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. Currently, U.S. GAAP requires entities to write down credit losses only when losses are probable and loss reversals are not permitted. The update is effective for the Company in the first quarter of 2020. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this standard will have on its consolidated financial statements and related disclosures.
Concentrations of Credit Risks	c. Concentrations of Credit Risks: Concentration of credit risk with respect to trade receivable is primarily limited to a customer to which the Company makes substantial sales. June 30, December 31, 2019 2018 Customer A 25 % * ) Customer B 25 % * ) Customer C 23 % * ) Customer D 20 % * ) Customer E * ) 28 % Customer F * ) 15 % Customer G * ) 14 % Customer H * ) 13 % Customer I * ) 12 % *) Less than 10% The Company’s trade receivables are geographically diversified and derived primarily from sales to customers in various countries, mainly in the United States and Europe. Concentration of credit risk with respect to trade receivables is limited by credit limits, ongoing credit evaluation and account monitoring procedures. The Company performs ongoing credit evaluations of its distributors based upon a specific review of all significant outstanding invoices. The Company writes off receivables when they are deemed uncollectible and having exhausted all collection efforts. As of June 30, 2019 and December 31, 2018 trade receivables are presented net of allowance for doubtful accounts in the amount of $31 thousand and $32 thousand, respectively, and net of sales return reserve of $86 thousand and $105 thousand as of June 30, 2019 and December 31, 2018, respectively.
Warranty provision	d. Warranty provision The Company provided a two-year standard warranty for its SCI products. In the beginning of 2018, we updated our service policy for new SCI Products sold to include a five-year warranty. ReStore service policy includes two-year warranty. The Company determined that the first two years of warranty is an assurance-type warranty and records a provision for the estimated cost to repair or replace products under warranty at the time of sale. Factors that affect the Company’s warranty reserve include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair. US Dollars in thousands Balance at December 31, 2018 $ 304 Provision 105 Usage (152 ) Balance at June 30, 2019 $ 257

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Schedule of disaggregation of revenues	Three Months Ended Six Months Ended 2019 2018 2019 2018 Units placed $ 772 $ 1,672 $ 2,246 $ 3,200 Spare parts and warranties 105 98 212 149 Total Revenues $ 877 $ 1,770 $ 2,458 $ 3,349
Schedule of trade receivables and deferred revunues	June 30, December 31, 2019 2018 Trade receivable, net (1) $ 417 $ 758 Deferred revenues (1) (2) $ 870 $ 668 (1) Balance presented net of unrecognized revenues that were not yet collected. (2) $184 thousand of December 31, 2018 deferred revenues balance were recognized as revenues during the six months ended June 30, 2019.
Schedule of concentration of credit risk	June 30, December 31, 2019 2018 Customer A 25 % * ) Customer B 25 % * ) Customer C 23 % * ) Customer D 20 % * ) Customer E * ) 28 % Customer F * ) 15 % Customer G * ) 14 % Customer H * ) 13 % Customer I * ) 12 % *) Less than 10%
Schedule of product warranty liability	US Dollars in thousands Balance at December 31, 2018 $ 304 Provision 105 Usage (152 ) Balance at June 30, 2019 $ 257

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2019
Inventory Disclosure [Abstract]
Summary of components of inventories	June 30, December 31, 2019 2018 Finished products $ 2,310 $ 2,240 Raw materials 351 — $ 2,661 $ 2,240

Commitments and Contingent Li_2

Commitments and Contingent Liabilities (Tables)	6 Months Ended
	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Schedule of future minimum lease commitments	2019 $ 345 2020 638 2021 613 2022 566 2023 439 Total lease payments 2,601 Less: imputed interest (562 ) Present value of future lease payments 2,039 Less: current maturities of operating leases (635 ) Non-current operating leases $ 1,404 Weighted-average remaining lease term (in years) 3.48 Weighted-average discount rate 12.5 %

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2019
Share-based Payment Arrangement [Abstract]
Schedule of Black-Scholes-Merton option pricing model assumptions	Six Months Ended 2019 2018 Expected volatility 57.5 % 57.19 - 61.12 % Risk-free rate 2.22 % 2.74% - 2.83 % Dividend yield — % — % Expected term (in years) 6.11 6.11 Share price $ 5.37 $ 26.88 - $28.75
Schedule of employee options activity	Number Average exercise price Average remaining contractual life (in years) Aggregate intrinsic value (in thousands) Options outstanding at the beginning of the period 72,655 $ 47.70 6.37 $ 114 Granted 12,425 5.37 Exercised — — Forfeited (5,371 ) 45.93 Options outstanding at the end of the period 79,709 $ 41.19 6.80 $ 393 Options exercisable at the end of the period 43,868 $ 56.49 4.96 $ —
Schedule of employee RSUs activity	Number of shares underlying outstanding RSUs Weighted Unvested RSUs at the beginning of the period 26,093 $ 48.78 Granted 87,436 4.69 Vested (16,656 ) 9.82 Forfeited (6,599 ) 17 Unvested RSUs at the end of the period 90,274 $ 37.49
Schedule of options and RSUs outstanding	Range of exercise price Options and RSUs outstanding as of Weighted average remaining contractual life (years) (1) Options Weighted average remaining contractual life (years) (1) RSUs only 90,274 — — — $5.37 12,425 9.75 — — $20.42 - $33.75 39,220 6.85 19,570 4.86 $37.14 - $38.75 12,740 4.44 12,740 4.44 $50 - $52.5 11,395 6.20 7,697 5.36 $182.5 - $524.25 3,929 6.40 3,861 6.40 169,983 6.80 43,868 4.96 (1) Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term.
Schedule of warrants outstanding and exercisable	Issuance date Warrants Exercise price per warrant Warrants outstanding and exercisable Contractual (number) (number) December 31, 2015 (1) 4,771 $ 7.500 4,771 See footnote (1) November 1, 2016 (2) 97,496 $ 118.750 97,496 November 1, 2021 December 28, 2016 (3) 1,908 $ 7.500 1,908 See footnote (1) November 20, 2018 (4) 126,839 $ 7.500 126,839 November 20, 2023 November 20, 2018 (5) 106,680 $ 9.375 106,680 November 15, 2023 February 25, 2019 (6) 45,600 $ 7.187 45,600 February 21, 2024 April 5, 2019 (7) 408,457 $ 5.140 408,457 October 7, 2024 April 5, 2019 (8) 49,015 $ 6.503 49,015 April 3, 2024 June 5, 2019 and June 6, 2019 (9) 1,464,665 $ 7.500 1,464,665 June 5, 2024 June 5, 2019 (10) 87,880 $ 9.375 87,880 June 5, 2024 June 12, 2019 (11) 416,667 $ 6.000 416,667 December 12, 2024 June 10, 2019 (12) 50,000 $ 7.500 50,000 June 10, 2024 2,859,978 2,859,978 (1) Represents warrants for ordinary shares issuable upon an exercise price of $7.5 per share, which were granted on December 31, 2015 to Kreos Capital V (Expert) Fund Limited, or Kreos, in connection with a loan made by Kreos to us and are currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of us with or into, or the sale or license of all or substantially all the assets or shares of us to, any other entity or person, other than a wholly-owned subsidiary of us, excluding any transaction in which our shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of June 30, 2019. (2) Represents warrants issued as part of our follow-on offering in November 2016. At any time, the board of directors may reduce the exercise price of the warrants to any amount and for any period of time it deems appropriate. (3) Represents common warrants that were issued as part of the $8.0 million drawdown under the Loan Agreement which occurred on December 28, 2016. See footnote 1 for exercisability terms. (4) Represents common warrants that were issued as part of our follow-on offering in November 2018. As of June 30, 2019, warrants to purchase an aggregate 1,651,537 ordinary shares had been exercised. (5) Represents common warrants that were issued to the underwriters as compensation for their role in our follow-on offering in November 2018. (6) Represents warrants that were issued to the exclusive placement agent as compensation for its role in our follow-on offering in February 2019. (7) Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in April 2019. (8) Represents warrants that were issued to the placement agent as compensation for its role in our April 2019 registered direct offering. (9) Represents warrants that were issued to certain institutional investors in a warrant exercise agreement on June 5, 2019 and June 6, 2019, respectively. (10) Represents warrants that were issued to the placement agent as compensation for its role in our June 2019 warrant exercise agreement and concurrent private placement of warrants. (11) Represents warrants that were issued to certain institutional investors in a warrant exercise agreement in June 2019. (12) Represents warrants that were issued to the placement agent as compensation for its role in our June 2019 registered direct offering and concurrent private placement of warrants.
Schedule of non-cash share-based compensation expense	Six Months Ended 2019 2018 Cost of revenues $ 7 $ 7 Research and development, net 124 203 Sales and marketing 126 300 General and administrative 376 1,309 Total $ 633 $ 1,819

Financial Expenses, Net (Tables

Financial Expenses, Net (Tables)	6 Months Ended
	Jun. 30, 2019
Other Income and Expenses [Abstract]
Schedule of financial expenses, net	Three Months Ended Six Months Ended 2019 2018 2019 2018 Foreign currency transactions and other $ (43 ) $ 58 $ (40 ) $ 39 Financial expenses related to loan agreement with Kreos 386 455 790 950 Bank commissions 10 9 21 18 $ 353 $ 522 $ 771 $ 1,007

Geographic Information and Ma_2

Geographic Information and Major Customer and Product Data (Tables)	6 Months Ended
	Jun. 30, 2019
Segment Reporting [Abstract]
Schedule of revenues within geographic areas	Three Months Ended Six Months Ended 2019 2018 2019 2018 Revenues based on customer's location : Israel $ 2 $ — $ 2 $ — United States 426 1,091 923 2,269 Europe 418 673 1,497 1,014 Asia-Pacific 31 6 36 8 Latin America — — — 58 Total revenues $ 877 $ 1,770 $ 2,458 $ 3,349
Schedule of long-lived assets by geographic region	June 30, December 31, 2019 2018 Long-lived assets by geographic region (*): Israel $ 181 $ 206 United States 236 330 Germany 36 90 $ 453 $ 626
Schedule of major customer data as a percentage of total revenues	Six Months Ended 2019 2018 Major customer data as a percentage of total revenues: Customer A 17.1 % 46.4 %

General (Details)

General (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	6 Months Ended
	Mar. 27, 2019	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
General (Textual)
Reverse share split	ratio of 1-for-25
Ordinary shares, par value (in NIS per share)	$ 0.25	$ 0.25		$ 0.25
Accumulated deficit		$ (161,505)		$ (152,918)
Negative cash flow from operations		$ (7,956)	$ (9,068)

Significant Accounting Polici_4

Significant Accounting Policies (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Total Revenues	$ 877	$ 1,770	$ 2,458	$ 3,349
Units Placed [Member]
Total Revenues	772	1,672	2,246	3,200
Spare parts and warranties [Member]
Total Revenues	$ 105	$ 98	$ 212	$ 149

Significant Accounting Polici_5

Significant Accounting Policies (Details 1) - USD ($) $ in Thousands		Jun. 30, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Trade receivable, net	[1]	$ 417	$ 758
Deferred revenues	[1],[2]	$ 870	$ 668
[1]	Balance presented net of unrecognized revenues that were not yet collected.
[2]	$184 thousand of December 31, 2018 deferred revenues balance were recognized as revenues during the six months ended June 30, 2019.

Significant Accounting Polici_6

Significant Accounting Policies (Details 2)	6 Months Ended		12 Months Ended
	Jun. 30, 2019		Dec. 31, 2018
Customer A [Member]
Concentration of credit risk	25.00%			[1]
Customer B [Member]
Concentration of credit risk	25.00%			[1]
Customer C [Member]
Concentration of credit risk	23.00%			[1]
Customer D [Member]
Concentration of credit risk	20.00%			[1]
Customer E [Member]
Concentration of credit risk		[1]	28.00%
Customer F [Member]
Concentration of credit risk		[1]	14.00%
Customer G [Member]
Concentration of credit risk		[1]	15.00%
Customer H [Member]
Concentration of credit risk		[1]	13.00%
Customer I [Member]
Concentration of credit risk		[1]	12.00%
[1]	Less than 10%

Significant Accounting Polici_7

Significant Accounting Policies (Details 3) $ in Thousands	6 Months Ended
	Jun. 30, 2019USD ($)
Warranty provision:
Balance at December 31, 2018	$ 304
Provision	105
Usage	(152)
Balance at June 30, 2019	$ 257

Significant Accounting Polici_8

Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Significant Accounting Policies (Textual)
Allowance for doubtful accounts	$ 31	$ 32
Net of sales return reserve	86	$ 105
Deferred revenues recognized	$ 184
Lease, description	Upon adoption of this standard on January 1, 2019, the Company recorded right?of?use assets and corresponding lease liabilities of $2,099 and $2,249, respectively. As of June 30, 2019, the right?of?use assets and corresponding lease liabilities in the Company's condensed consolidated balance sheets were $1,893 and $2,039, respectively.
Performance obligation, description	The estimated revenue expected to be recognized in the future related to the service type warranty amounts to $874 thousand, which is fulfilled over one to five years.

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Finished products	$ 2,310	$ 2,240
Raw materials	351
Inventories	$ 2,661	$ 2,240

Commitments and Contingent Li_3

Commitments and Contingent Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
2019	$ 345
2020	638
2021	613
2022	566
2023	439
Total lease payments	2,601
Less: imputed interest	(562)
Present value of future lease payments	2,039
Less: current maturities of operating leases	635
Non-current operating leases	$ 1,404
Weighted-average remaining lease term (in years)	3 years 5 months 23 days
Weighted-average discount rate	12.50%

Commitments and Contingent Li_4

Commitments and Contingent Liabilities (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Commitments and Contingent Liabilities (Textual)
Non-cancelable outstanding obligations	$ 1,350		$ 1,350
Maximum penalties payable on early release of agreement	44		44
Royalties expenses			$ 5
Lease expiration, term			These leases expire between 2019 and 2023.
Other long-term assets	810		$ 810
Lease expense	180	$ 187	$ 360	$ 375
IPO [Member]
Commitments and Contingent Liabilities (Textual)
Description of conversion ratio			Ordinary shares in a conversion ratio of 1 to 1.
Israel Innovation Authority [Member]
Commitments and Contingent Liabilities (Textual)
Total fund received			$ 1,970
Royalty bearing grants			1,570
Royalties paid			50
Contingent liability	$ 1,500		$ 1,500
Percentage of grant received			100.00%
Israel Innovation Authority [Member] | Convertible preferred A shares [Member]
Commitments and Contingent Liabilities (Textual)
Amount received in consideration of preferred shares			$ 400
Convertible preferred shares	209		209
Israel Innovation Authority [Member] | Minimum [Member]
Commitments and Contingent Liabilities (Textual)
Percentage of obligation to pay royalties			3.00%
Israel Innovation Authority [Member] | Maximum [Member]
Commitments and Contingent Liabilities (Textual)
Percentage of obligation to pay royalties			3.50%
Israel US Binational Industrial Research And Development Foundation [Member]
Commitments and Contingent Liabilities (Textual)
Total fund received			$ 500
Percentage of obligation to pay royalties			5.00%
Israel US Binational Industrial Research And Development Foundation [Member] | Maximum [Member]
Commitments and Contingent Liabilities (Textual)
Percentage of obligation to pay royalties			150.00%
RRL and RRG [Member]
Commitments and Contingent Liabilities (Textual)
Lease expiration, term			RRL and RRG lease cars for their employees under cancelable operating lease agreements expiring at various dates in between 2019 and 2022.
Kreos Capital V [Member]
Commitments and Contingent Liabilities (Textual)
Line of credit	$ 20,000		$ 20,000

Research Collaboration Agreem_2

Research Collaboration Agreement and License Agreement (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Research Collaboration Agreement and License Agreement (Textual)
Research and development expenses	$ 1,860	$ 1,897	$ 3,274	$ 4,048
License Agreement and Collaboration Agreement [Member]
Research Collaboration Agreement and License Agreement (Textual)
Total payment obligation			7,100
Research and development expenses	$ 868		$ 1,112
Research collaboration agreement expire date			May 16, 2022

Shareholders' Equity (Details)

Shareholders' Equity (Details) - $ / shares	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Share-based Payment Arrangement [Abstract]
Expected volatility	57.50%	61.12%
Risk-free rate	2.22%	2.74%
Dividend yield
Expected term (in years)	6 years 1 month 9 days	6 years 1 month 9 days
Share price	$ 5.37	$ 28.75

Shareholders' Equity (Details 1

Shareholders' Equity (Details 1) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Share-based Payment Arrangement [Abstract]
Number Options outstanding at the beginning of the period	72,655
Number, Granted	12,425
Number, Exercised
Number, Forfeited	(5,371)
Number, Options outstanding at the end of the period	79,709	72,655
Number, Options exercisable at the end of the period	43,868
Average exercise price, Options outstanding at the beginning of the period	$ 47.7
Average exercise price, Granted	5.37
Average exercise price, Exercised
Average exercise price, Forfeited	45.93
Average exercise price, Options outstanding at the end of the period	41.19	$ 47.7
Average exercise price, Options exercisable at the end of the period	$ 56.49
Average remaining contractual life (in years), Options outstanding at the beginning of the period	6 years 9 months 18 days	6 years 4 months 13 days
Average remaining contractual life (in years), Options exercisable at the end of the period	4 years 11 months 15 days
Aggregate intrinsic value (in thousands), Options outstanding	$ 393	$ 114
Aggregate intrinsic value (in thousands), Options exercisable at the end of the period

Shareholders' Equity (Details 2

Shareholders' Equity (Details 2) - Employee RSUs [Member]	6 Months Ended
	Jun. 30, 2019$ / sharesshares
Number of shares underlying outstanding RSUs
Unvested RSUs at the end of the period | shares	26,093
Granted | shares	87,436
Vested | shares	(16,656)
Forfeited | shares	(6,599)
Unvested RSUs at the end of the period | shares	90,274
Weighted average grant date fair value
Unvested RSUs at the end of the period | $ / shares	$ 48.78
Granted | $ / shares	4.69
Vested | $ / shares	9.82
Forfeited | $ / shares	17
Unvested RSUs at the end of the period | $ / shares	$ 37.49

Shareholders' Equity (Details 3

Shareholders' Equity (Details 3) - Options and RSUs [Member]	6 Months Ended
	Jun. 30, 2019$ / sharesshares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding	169,983
Options outstanding weighted average remaining contractual life (years)	6 years 9 months 18 days	[1]
Options outstanding and exercisable	43,868
Options exercisable weighted average remaining contractual life (years)	4 years 11 months 15 days	[1]
Exercise Price Range One [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 5.37
Options outstanding	12,425
Options outstanding weighted average remaining contractual life (years)	9 years 9 months	[1]
Options outstanding and exercisable
Options exercisable weighted average remaining contractual life (years)	0 years	[1]
Exercise Price Range Two [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price, minimum | $ / shares	$ 20.42
Range of exercise price, maximum | $ / shares	$ 33.75
Options outstanding	39,220
Options outstanding weighted average remaining contractual life (years)	6 years 10 months 6 days	[1]
Options outstanding and exercisable	19,570
Options exercisable weighted average remaining contractual life (years)	4 years 10 months 10 days	[1]
Exercise Price Range Three [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price, minimum | $ / shares	$ 37.14
Range of exercise price, maximum | $ / shares	$ 38.75
Options outstanding	12,740
Options outstanding weighted average remaining contractual life (years)	4 years 5 months 9 days	[1]
Options outstanding and exercisable	12,740
Options exercisable weighted average remaining contractual life (years)	4 years 5 months 9 days	[1]
Exercise Price Range Four [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price, minimum | $ / shares	$ 50
Range of exercise price, maximum | $ / shares	$ 52.5
Options outstanding	11,395
Options outstanding weighted average remaining contractual life (years)	6 years 2 months 12 days	[1]
Options outstanding and exercisable	7,697
Options exercisable weighted average remaining contractual life (years)	5 years 4 months 9 days	[1]
Exercise Price Range Five [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price, minimum | $ / shares	$ 182.5
Range of exercise price, maximum | $ / shares	$ 524.25
Options outstanding	3,929
Options outstanding weighted average remaining contractual life (years)	6 years 4 months 24 days	[1]
Options outstanding and exercisable	3,861
Options exercisable weighted average remaining contractual life (years)	6 years 4 months 24 days	[1]
Exercise Price Range [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
RSUs outstanding	90,274
Options outstanding weighted average remaining contractual life (years)	0 years	[1]
Options outstanding and exercisable
Options exercisable weighted average remaining contractual life (years)	0 years	[1]
[1]	Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term.

Shareholders' Equity (Details 4

Shareholders' Equity (Details 4)	6 Months Ended
	Jun. 30, 2019$ / sharesshares
Class of Warrant or Right [Line Items]
Warrants outstanding	2,859,978
Warrants outstanding and exercisable	2,859,978
November 1, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	97,496	[1]
Exercise price per warrant | $ / shares	$ 118.75	[1]
Warrants outstanding and exercisable	97,496	[1]
Warrants term	Nov. 1, 2021	[1]
November 20, 2018 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	1,767,710	[2]
Exercise price per warrant | $ / shares	$ 7.5	[2]
Warrants outstanding and exercisable	1,767,710	[2]
Warrants term	Nov. 20, 2023	[2]
November 20, 2018 One [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	106,680	[3]
Exercise price per warrant | $ / shares	$ 9.375	[3]
Warrants outstanding and exercisable	106,680	[3]
Warrants term	Nov. 15, 2023	[3]
February 25, 2019 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	45,600	[4]
Exercise price per warrant | $ / shares	$ 7.1875	[4]
Warrants outstanding and exercisable	45,600	[4]
Warrants term	Feb. 21, 2024	[4]
December 31, 2015 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	4,771	[5]
Exercise price per warrant | $ / shares	$ 7.5	[5]
Warrants outstanding and exercisable	4,771	[5]
December 28, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	1,908	[6]
Exercise price per warrant | $ / shares	$ 7.5	[6]
Warrants outstanding and exercisable	1,908	[6]
April 5, 2019 [Memeber]
Class of Warrant or Right [Line Items]
Warrants outstanding	408,457	[7]
Exercise price per warrant | $ / shares	$ 5.14	[7]
Warrants outstanding and exercisable	408,457	[7]
Warrants term	Oct. 7, 2024	[7]
April 5, 2019 One [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	49,015	[8]
Exercise price per warrant | $ / shares	$ 6.503	[8]
Warrants outstanding and exercisable	49,015	[8]
Warrants term	Apr. 3, 2024	[8]
June 5, 2019 and June 6, 2019 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	1,464,665	[9]
Exercise price per warrant | $ / shares	$ 7.5	[9]
Warrants outstanding and exercisable	1,464,665	[9]
Warrants term	Jun. 5, 2024	[9]
June 5, 2019 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	87,880	[10]
Exercise price per warrant | $ / shares	$ 9.375	[10]
Warrants outstanding and exercisable	87,880	[10]
Warrants term	Jun. 5, 2024	[10]
June 12, 2019 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	416,667	[11]
Exercise price per warrant | $ / shares	$ 6	[11]
Warrants outstanding and exercisable	416,667	[11]
Warrants term	Dec. 12, 2024	[11]
June 10, 2019 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	50,000	[12]
Exercise price per warrant | $ / shares	$ 7.5	[12]
Warrants outstanding and exercisable	50,000	[12]
Warrants term	Jun. 10, 2024	[12]
[1]	Represents warrants issued as part of our follow-on offering in November 2016. At any time, the board of directors may reduce the exercise price of the warrants to any amount and for any period of time it deems appropriate.
[2]	Represents common warrants that were issued as part of our follow-on offering in November 2018. As of June 30, 2019, warrants to purchase an aggregate 1,651,537 ordinary shares had been exercised.
[3]	Represents common warrants that were issued to the underwriters as compensation for their role in our follow-on offering in November 2018.
[4]	Represents warrants that were issued to the exclusive placement agent and its designees as compensation for their role in our follow-on offering in February 2019.
[5]	Represents warrants for ordinary shares issuable upon an exercise price of $7.5 per share, which were granted on December 31, 2015 to Kreos Capital V (Expert) Fund Limited, or Kreos, in connection with a loan made by Kreos to us and are currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of us with or into, or the sale or license of all or substantially all the assets or shares of us to, any other entity or person, other than a wholly-owned subsidiary of us, excluding any transaction in which our shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of June 30, 2019.
[6]	Represents common warrants that were issued as part of the $8.0 million drawdown under the Loan Agreement which occurred on December 28, 2016. See footnote 1 for exercisability terms.
[7]	Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in April 2019.
[8]	Represents warrants that were issued to the placement agent as compensation for its role in our April 2019 registered direct offering.
[9]	Represents warrants that were issued to certain institutional investors in a warrant exercise agreement on June 5, 2019 and June 6, 2019, respectively.
[10]	Represents warrants that were issued to the placement agent as compensation for its role in our June 2019 warrant exercise agreement and concurrent private placement of warrants.
[11]	Represents warrants that were issued to certain institutional investors in a warrant exercise agreement in June 2019.
[12]	Represents warrants that were issued to the placement agent as compensation for its role in our June 2019 registered direct offering and concurrent private placement of warrants.

Shareholders' Equity (Details 5

Shareholders' Equity (Details 5) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Non-cash share-based compensation expense	$ 633	$ 1,819
Cost of revenues [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Non-cash share-based compensation expense	7	7
Research and development, net [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Non-cash share-based compensation expense	124	203
Sales and marketing [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Non-cash share-based compensation expense	126	300
General and administrative [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Non-cash share-based compensation expense	$ 376	$ 1,309

Shareholders' Equity (Details T

Shareholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands

May 15, 2018

May 10, 2016

Jun. 12, 2019

Jun. 06, 2019

Jun. 05, 2019

Apr. 30, 2019

Mar. 27, 2019

Feb. 28, 2019

Nov. 30, 2018

May 31, 2018

Mar. 06, 2018

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Dec. 31, 2015

Dec. 31, 2018

Apr. 30, 2018

Dec. 28, 2016

Shareholders' Equity (Textual)

Reverse share split, description

ratio of 1-for-25

The Company’s shareholders approved (i) a reverse share split within a range of 1:8 to 1:32, to be effective at the ratio and on a date to be determined by the Board of Directors, and (ii) amendments to the Company’s Articles of Association authorizing an increase in the Company’s authorized share capital (and corresponding authorized number of ordinary shares, proportionally adjusting such number for the reverse share split) by up to NIS 17.5 million. Following the shareholder approval, an authorized committee of the Board of Directors of the Company approved a one-for-twenty-five reverse share split of the Company’s ordinary shares, and the Company filed the Third Amended and Restated Articles of Association of the Company with the Registrar of Companies of the State of Israel to effect the reverse share split and to increase the Company’s authorized share capital after the effect of the reverse share split. The reverse share split became effective on April 1, 2019. Additionally, effective at the same time, the total number of ordinary shares the Company is authorized to issue changed from 250,000,000 shares to 60,000,000 shares, the par value per share of the ordinary shares changed to NIS 0.25 and the authorized share capital of the Company changed from NIS 2,500,000 to NIS 15,000,000. All share and per share data included in these condensed consolidated financial statements give retroactive effect to the reverse stock split for all periods presented.

Issuance of ordinary shares in an ATM offering of ordinary shares, net of issuance expenses

$ 714

$ 1,062

Options granted (in shares)

12,425

Expected term of shares

6 years 1 month 9 days

6 years 1 month 9 days

Warrant exercised

$ 1,651,537

Description of underwriting agreement

The Company entered into an underwriting agreement with H.C. Wainwright, in connection with the Company’s follow-on public offering of 496,040 units, each consisting of one ordinary share and one common warrant to purchase one ordinary share with an exercise price of $7.5 per warrant. Each unit was sold to the public at a price of $7.50 per unit. On November 18, 2018, H.C. Wainwright exercised in full its option to purchase 231,964 ordinary shares for $7.25 per share and/or common warrants to purchase up to an additional 231,964 ordinary shares for $0.25 per warrant.

Description of underwriters warrants to purchase

The company issued and sold 1,050,372 pre-funded units at a price to the public of $7.25 per unit. Each unit containing one pre-funded warrant with an exercise price of $0.25 per share and one warrant to purchase one ordinary share with an exercise price of $7.50 per warrant. The total gross proceeds received from the November 2018 follow-on public offering, before deducting commissions, discounts and expenses, were $13.1 million (including proceeds from the exercise of 90,691 pre-funded warrants at the closing of the offering). As of December 31, 2018, additional pre-funded warrants to purchase an aggregate 562,466 ordinary shares had been exercised, for additional proceeds of $140,617. During the three months ended March 31, 2019 additional pre-funded warrants and warrants to purchase an aggregate 119,881 ordinary shares had been exercised, for additional proceeds of $107,303. As compensation for their role in the offering, the Company also issued to the Underwriters warrants to purchase up to 106,680 ordinary shares, which became immediately exercisable starting on November 20, 2018 until November 15, 2023 at $9.375 per share.

Securities Purchase Agreements [Member]

Shareholders' Equity (Textual)

Exercise price per share

$ 6

$ 5.14

Number of warrants issued

416,667

408,457

Warrants exercisable, description

Exercisable from June 12, 2019 until December 12, 2024.

Exercisable from June 5, 2019 or June 6, 2019 until June 5, 2024 or June 6, 2024.

Exercisable from June 5, 2019 or June 6, 2019 until June 5, 2024 or June 6, 2024.

Exercisable from April 5, 2019 until October 7, 2024.

Issuance of ordinary shares, shares

833,334

1,464,665

1,464,665

816,914

Exercise price ordinary shares

$ 6

$ 7.50

$ 7.50

$ 5.2025

Securities Purchase Agreements [Member] | NIS [Member]

Shareholders' Equity (Textual)

Exercise price ordinary shares

$ 0.25

Securities Purchase Agreements [Member] | Addtional Warrant to Purchase [Member]

Shareholders' Equity (Textual)

Warrants exercisable, description

Exercisable from June 12, 2019 until June 10, 2024.

Exercisable from June 5, 2019 until June 5, 2024.

Exercisable from June 5, 2019 until June 5, 2024.

Exercisable from April 5, 2019 until April 3, 2024.

Issuance of ordinary shares, shares

50,000

87,880

87,880

49,015

Exercise price ordinary shares

$ 7.50

$ 9.375

$ 9.375

$ 6.503125

Kreos Capital V [Member]

Shareholders' Equity (Textual)

Warrants grant date

Dec. 31, 2015

Warrants exercisable, description

Currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of us with or into, or the sale or license of all or substantially all the assets or shares of us to, any other entity or person, other than a wholly-owned subsidiary of us, excluding any transaction in which our shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction.

Restricted Stock Units (RSUs) [Member]

Shareholders' Equity (Textual)

Weighted average grant date fair value, restricted stock units (in USD per share)

$ 4.69

$ 27.50

Weighted average grant date fair value, options (in USD per share)

$ 2.98

$ 15.25

Employee Stock Option And Restricted Stock Units Rsu [Member]

Shareholders' Equity (Textual)

RSUs granted (in shares)

87,436

Employee Stock Option [Member]

Shareholders' Equity (Textual)

Award vesting period, description

Options to purchase ordinary shares generally vest over four years, with certain options to non-employee directors vesting quarterly over one year.

Shares reserved for future issuance (in shares)

3,287

52,298

Unrecognized cost of shares

$ 1,750

Expected term of shares

1 year 10 months 17 days

Canacord Gunuity Inc [Member]

Shareholders' Equity (Textual)

Issuance of ordinary shares (in shares)

4,715

Timwell Corporation Limited [Member]

Shareholders' Equity (Textual)

Aggregate number of ordinary shares

640,000

Gross proceeds

$ 20,000

Fees and other related expenses

705

Net aggregate proceeds of after deducting fees and other related expenses

$ 4,300

Description of tranche consisting

The Company entered into a fee and release agreement with Canaccord Genuity LLC (“Canaccord Genuity”) requiring the Company to pay to Canaccord Genuity, in connection with a settlement, in addition to certain cash amounts, (i) $125 thousand in ordinary shares of the Company after the First Tranche Closing of the Timwell transaction and (ii) $225 thousand in ordinary shares of the Company after the closing of the Second Tranche of the Timwell transaction (or such lower amount if the Second Tranche Closing is less than $10.0 million). The price per share used for calculation of the number of ordinary shares issued by the Company to Canaccord Genuity is based on the volume weighted average price of the Company’s ordinary shares as reported on the Nasdaq Capital Market for the five consecutive trading days prior to the date of issuance. The Company is also obligated to pay $100 thousand in cash following the closing of the Third Tranche of $5.0 million (or such lower amount if the Third Tranche Closing is less than $5.0 million). Following the First Tranche Closing in May 15, 2018, the Company issued 4,715 ordinary shares to Canaccord Genuity.

The Company entered into an investment agreement with Timwell Corporation Limited, a Hong Kong corporation (“Timwell”), as amended on May 15, 2018 (the “Investment Agreement”), pursuant to which the Company agreed to issue to Timwell, in three different tranches, an aggregate of 640,000 ordinary shares in return for aggregate gross proceeds of $20 million. The closing of each tranche is subject to certain closing conditions. The closing of the first tranche (the “First Tranche Closing”) took place on May 15, 2018, upon which Timwell received 160,000 ordinary shares for an aggregate purchase price of $5,000,000, and Timwell and the Company signed a registration rights agreement in the form attached to the Investment Agreement. The net aggregate proceeds of the First Tranche Closing after deducting fees and other related expenses in the amount of approximately $705 thousands were approximately $4.3 million. The remaining investment is to occur in two tranches, including $10 million for the issuance to Timwell of 320,000 ordinary shares (the “Second Tranche”) and $5 million for the issuance to Timwell of 160,000 ordinary shares (the “Third Tranch”). The closing of the second and third tranches is subject to specified closing conditions, including, with respect to the second tranche, the signing of a license agreement and a supply agreement and the formation of the China JV (the “China JV”) based on the JV Framework Agreement, and, with respect to the third tranche, the successful production of certain ReWalk products by the China JV. The second tranche closing was initially expected to occur by July 1, 2018 and the third tranche closing was initially expected to occur by December 31, 2018 and no later than April 1, 2019.

Kreos Capital [Member]

Shareholders' Equity (Textual)

Exercise price per share

$ 7.5

Drawdown amount under loan agreement

$ 8,000

Atm Offering Program [Member]

Shareholders' Equity (Textual)

Aggregate offering price

$ 25,000

Stock issuance costs under equity distribution agreement as a percent of gross proceeds

3.00%

Issuance of ordinary shares (in shares)

302,092

Issuance of ordinary shares in an ATM offering of ordinary shares, gross of issuance expenses

$ 15,700

Issuance of ordinary shares in an ATM offering of ordinary shares, net of issuance expenses

$ 14,500

Fixed commission rate

3.00%

Fixed commission amount

$ 471

Issuance expenses

109

$ 109

Proceeds percentage of sale of the ordinary shares

8.00%

Fees and other related expenses

1,171

Private Placement Agreement [Member]

Shareholders' Equity (Textual)

Issuance of ordinary shares (in shares)

760,000

Sale of stock price per share

$ 5.75

Total gross proceeds received from the follow-on public offering

$ 4,370

Description of wainwright or its designees warrants to purchase

The Company also issued to H.C Wainwright and/or its designees warrants to purchase up to 45,600 ordinary shares, which are immediately exercisable starting on February 25, 2019 until February 21, 2024 at $7.1875 per share.

Best Offering [Member]

Shareholders' Equity (Textual)

Issuance expenses

$ 686

$ 686

Financial Expenses, Net (Detail

Financial Expenses, Net (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Other Income and Expenses [Abstract]
Foreign currency transactions and other	$ (43)	$ 58	$ (40)	$ 39
Financial expenses related to loan agreement with Kreos	386	455	790	950
Bank commissions	10	9	21	18
Financial expenses, net	$ 353	$ 522	$ 771	$ 1,007

Geographic Information and Ma_3

Geographic Information and Major Customer and Product Data (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenue, Major Customer [Line Items]
Total revenues	$ 877	$ 1,770	$ 2,458	$ 3,349
Israel [Member]
Revenue, Major Customer [Line Items]
Total revenues	2		2
United States [Member]
Revenue, Major Customer [Line Items]
Total revenues	923	2,269	426	1,091
Europe [Member]
Revenue, Major Customer [Line Items]
Total revenues	1,497	1,014	418	673
Asia-Pacific [Member]
Revenue, Major Customer [Line Items]
Total revenues	36	8	31	6
Latin America [Member]
Revenue, Major Customer [Line Items]
Total revenues		$ 58

Geographic Information and Ma_4

Geographic Information and Major Customer and Product Data (Details 1) - USD ($) $ in Thousands		Jun. 30, 2019	Dec. 31, 2018
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets		$ 453	$ 626
Israel [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	[1]	181	206
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	[1]	236	330
Germany [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	[1]	$ 36	$ 90
[1]	Long-lived assets are comprised of property and equipment, net.

Geographic Information and Ma_5

Geographic Information and Major Customer and Product Data (Details 2)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Customer A [Member] | Sales Revenue, Net [Member]
Revenue, Major Customer [Line Items]
Concentration risk	17.10%	46.40%

Geographic Information and Ma_6

Geographic Information and Major Customer and Product Data (Details Textual)	6 Months Ended
	Jun. 30, 2019segment
Geographic Information and Major Customer and Product Data (Textual)
Number of reportable segments	1